Shots: The P-I/III (NCT02792699) study involves assessing of ABP 798 vs Rituxan (rituximab, IV) in 311 patients in the ratio (1:1:1) with moderate-to-severe RA, evaluating safety, efficacy, and PK for 48 wks. The […]readmore
Tags : Rheumatoid Arthritis (RA)